Payload Information
General Information of This Payload
| Payload ID | PAY0WSDZI |
|||||
|---|---|---|---|---|---|---|
| Name | WO2024020536A1+HER-E-44+payload |
|||||
| Synonyms |
WO2024020536A1+HER-E-44+payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C24H21FN2O4 |
|||||
| Isosmiles | CC[C@]1(O)C(C=C2C3=NC4=C5C(CCCC5=C3CN26)=C(C)C(F)=C4)=C(COC1=O)C6=O |
|||||
| InChI |
InChI=1S/C24H21FN2O4/c1-3-24(30)16-7-19-21-14(9-27(19)22(28)15(16)10-31-23(24)29)13-6-4-5-12-11(2)17(25)8-18(26-21)20(12)13/h7-8,30H,3-6,9-10H2,1-2H3/t24-/m0/s1
|
|||||
| InChIKey |
YLGVBUAQTQSHCD-DEOSSOPVSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
420.44 |
Polar area |
81.42 |
||
Complexity |
1374.129539 |
xlogp Value |
3.01582 |
|||
Heavy Count |
31 |
Rot Bonds |
1 |
|||
Hbond acc |
6 |
Hbond Donor |
1 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
HER-E-44 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
. pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
HER-E-46 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
35.06 pM
|
High HER2 expression (HER2 +++) | ||
| Method Description |
A Cell line test on SKBR-3
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||